ADVERTISEMENT
Search

January 2022

Pharmacy Today logo
Volume 28, Issue 1

Archives   Download TOC  

Current Issue

January 2022 cover

Download  

ADVERTISEMENT
 

Practice & Trends

Inadvertent intra-arterial promethazine injury
Practice & Trends

Error Alert

Inadvertent intra-arterial promethazine injury

Many health care professionals know that promethazine injection is a vesicant and is highly caustic to the intima of blood vessels and surrounding tissue. Parenteral administration can result in severe tissue damage, regardless of the route of administration.

Institute for Safe Medication Practices, Horsham, PA

RSS
2022: Achieving a sustainable model

Association Perspective

2022: Achieving a sustainable model

We started 2021 with hope. We finally had vaccines and pharmacy was perfectly positioned to save the world. Unfortunately, hopes of quickly vaccinating out of the pandemic were dashed by vaccine hesitancy and rapidly mutating variants.

Scott J. Knoer, MS, PharmD, FASHP, APhA executive vice president and CEO

Looking forward to a bright future
Today's Perspective

Today's Perspective

Looking forward to a bright future

It is with the benefit of time and experience that we look back on days past. From this perspective, there are lessons to learn and wisdom to gain, which can and will shape our future.

Kristin Wiisanen, PharmD, FAPhA, FCCP, Pharmacy Today editor in chief

RSS

Drugs & Diseases

Drugs & Diseases

Immunization Update

ACIP issues recommendations for zoster, pneumococcal vaccines

At a recent meeting of CDC’s Advisory Committee of Immunization Practices (ACIP), the group recommended recombinant zoster vaccine (RZV) for adults 19 years and older who are immunodeficient or immunosuppressed as well as the routine use of select pneumococcal vaccines in adults 65 years and older and those aged 19 to 64 years with certain underlying medical conditions or other risk factors.

Maria G. Tanzi, PharmD

Do ditans and gepants have a place in acute migraine treatment?
Drugs & Diseases

Migraine

Do ditans and gepants have a place in acute migraine treatment?

A systematic review and meta-analysis by Yang and colleagues, published in JAMA Open Network in October 2021, found that 5-HT1F receptor agonists or “ditans” (lasmiditan) and calcitonin gene-related peptide antagonists or “gepants” (rimegepant and ubrogepant) were not as effective in reducing pain 2 hours post-dose as compared to triptans.

Clarissa Chan, PharmD

Insomnia
Drugs & Diseases

OTCs Today

Insomnia

Welcome to 2022! As we continue to navigate stressful and uncertain times, an issue such as insomnia—normally a fairly common complaint— will become even more prevalent.

Daniel L. Krinsky, BS, MS, RPh, FAPhA

RSS

Health Systems

Empagliflozin may be beneficial in acute HF
Health Systems

Heart Failure

Empagliflozin may be beneficial in acute HF

Adults treated with empagliflozin (Jardiance—Boehringer Ingelheim, Lilly) during hospitalization for an acute heart failure (HF) event had reduced all-cause mortality, fewer HF events, and improvement in HF–related symptoms compared with those given a placebo, according to results of the EMPULSE trial presented at the 2021 American Heart Association (AHA) Scientific Sessions.

Maria G. Tanzi, PharmD

RSS

CPE

RSS

In this Issue

RSS
ADVERTISEMENT